GlassScriptPhysician profile
Nanjappa Chandramohan
NPI 1699772574
$1,519.08
in general payments reported to CMS, 2019-2025
24 companies · $486 in 2025
The $486 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $60.54 · 2022: $224 · 2023: $239 · 2024: $405 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $368.62 | 2023-2025 | Evenity, Tepezza, Prolia |
| Sanofi-Aventis U.S. LLC | $183.15 | 2020-2023 | |
| Medtronic, INC. | $160.94 | 2024-2025 | Minimed 780g |
| Kaneka Medical America LLC | $104.09 | 2019 | |
| Novo Nordisk INC | $95.60 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $94.59 | 2025 | Zepbound, Mounjaro |
| Neurocrine Biosciences, INC. | $49.38 | 2025 | |
| Dexcom, INC. | $48.04 | 2022-2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $45.85 | 2025 | Korlym |
| Sequel Med Tech, LLC | $44.55 | 2025 | Twiist |
| Insulet Corporation | $39.42 | 2022-2024 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $32.04 | 2022-2025 | |
| Tandem Diabetes Care, INC. | $31.13 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $30.84 | 2023 | Lo Loestrin Fe |
| Rhythm Pharmaceuticals, INC. | $27.27 | 2025 | Imcivree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $22.40 | 2023 | |
| Beta Bionics, INC. | $22.23 | 2024 | Ilet Bionic Pancreas |
| Madrigal Pharmaceuticals | $22.21 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.05 | 2022 | |
| Merck Sharp & Dohme LLC | $16.41 | 2022 | |
| Kyowa Kirin, INC. | $16.28 | 2024 | Crysvita |
| Agile Therapeutics, INC. | $15.21 | 2022 | |
| Abbott Laboratories | $13.51 | 2023 | Freestyle Libre 3 |
| Millicent US INC | $13.27 | 2023 | Femring, Intrarosa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanjappa Chandramohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.